reports
XL Holdings Berhad: 1 director
A director at XL Holdings Berhad bought 4,200,000 shares at 0.687MYR and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
- Oluebube Nwosu
GUINNESS NIGERIA PLC 9M'24 Earnings Release - Macro headwinds drag per...
Topline expands on price increases.In Q3’24, Guinness Nigeria demonstrated robust revenue growth, despite the prevailing macro challenges. The company delivered a satisfactory topline performance, driven primarily by increased pricing amid a decline in sales volume. Revenue for the quarter surged 44% y/year to ₦77.7 billion, as a result of this higher pricing.However, the company’s margins came under pressure due to rising costs. The jump in cost of sales outpaced revenue growth, rising by...
EQS-News: CPI PROPERTY GROUP – Sale of Crans Montana Ski Resort
EQS-News: CPI PROPERTY GROUP / Key word(s): Real Estate CPI PROPERTY GROUP – Sale of Crans Montana Ski Resort 02.05.2024 / 13:56 CET/CEST The issuer is solely responsible for the content of this announcement. CPI Property Group (société anonyme) 40, rue de la Vallée L-2661 Luxembourg R.C.S. Luxembourg: B 102 254 Press Release - Corporate News Luxembourg, 2 May 2024CPI PROPERTY GROUP – Sale of Crans Montana Ski Resort CPI PROPERTY GROUP (“CPIPG” or th...
Mersana Therapeutics to Host First Quarter 2024 Conference Call on May...
Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024 CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the first quarter ended March 31, 2024 on Thursday, May 9, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that m...
Edda Wind ASA: 3 directors
Three Directors at Edda Wind ASA sold/bought 32,316,131 shares at 24.500NOK. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
IOI Properties Group Berhad: 1 director
A director at IOI Properties Group Berhad sold 47,530,000 shares at 2.052MYR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
New York Jets Announce Multi-Year Partnership with VitaCholine®
New York Jets Announce Multi-Year Partnership with VitaCholine® First Professional Sports Partnership for VitaCholine® encompasses rights across regions including the United States and the United Kingdom. MONTVALE, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- The New York Jets announced a partnership with VitaCholine, a Balchem Human Nutrition and Health brand of the essential nutrient choline, as Proud Partner of the team. This agreement marks VitaCholine’s first sponsorship and the first sponsorship in the Nutritional Ingredient category of a major professional sports team. The multi-year a...
Positive Initial Clinical Data Reported from Immutep’s Efti Combined w...
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma Media Release Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trialFour of six patients treated have very good, near-complete pathologic responses (primary endpoint of study) that are rarely observed with standard therapiesSoft tissue sarcoma is a hard-to-treat orphan disease with poor prognosis & high unmet medical ne...
Charles River Launches Viral Vector Reference Materials to Streamline ...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, designed to streamline Cell and Gene Therapy (CGT) research and development as it scales to Good Manufacturing Practice- (GMP) quality. Moving towards a gold standard for reference materials, Charles River is introducing six AAV reference material serotypes, offering superior and capsid ratios and high vector genome concentration (GC/mL), plus five products, available wi...
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Ach...
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer Boston (May 2, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the early discontinuation of its Phase 2 clinical trial of stenoparib, a novel PARP inhibitor, for the treatment of advanced recurrent ovarian cancer. The patients enrolled in the trial had been pre-screened by Allarity’s uniq...
LifeMD Becomes the First Virtual Primary Care Provider to Elevate GLP-...
LifeMD Becomes the First Virtual Primary Care Provider to Elevate GLP-1 Patient Care with Real-time, At-Home Monitoring of Blood Pressure and Body Composition LifeMD and Withings Health Solutions partnership exemplifies the potential of digital health technology to transform virtual patient care and improve outcomes NEW YORK and BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LFMD), a leading provider of virtual primary care services, and , a leader in digital health technology, announce a new strategic partnership designed to revolutionize weight management patient care by providing...
Lineage Cell Therapeutics to Report First Quarter 2024 Financial Resul...
CARLSBAD, Calif.--(BUSINESS WIRE)-- (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 9, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2024 financial and operating results and to provide a business update. Interested parties ma...
Arbe to Participate at the Oppenheimer 9th Annual Emerging Growth Conf...
Arbe to Participate at the Oppenheimer 9th Annual Emerging Growth Conference Tel Aviv, Israel, May 2, 2024— Ltd. (Nasdaq: ARBE) (“Arbe”), a global leader in Perception Radar solutions, today announced that Kobi Marenko, Chief Executive Officer, and Karine Pinto-Flomenboim, Chief Financial Officer, participate virtually at the Oppenheimer 9th Annual Emerging Growth Conference on Thursday, May 9, 2024. Arbe will hold one-on-one investor meetings during the day. Please contact your Oppenheimer salesperson to schedule a meeting. For more information regarding this event, please visit Arbe’s ...
Aspira Women’s Health Enhances its Commercial Offering with the Formal...
Aspira Women’s Health Enhances its Commercial Offering with the Formal Launch of Longitudinal Monitoring Feature of OvaWatch AUSTIN, Texas, May 02, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the formal launch of an updated OvaWatch ovarian cancer risk assessment test following the completion of all appropriate pre-launch activities. Adnexal masses develop near the uterus, usually in or around the ovaries, f...
Milestone® Pharmaceuticals Announces Data Presentations on Etripamil a...
Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024 MONTREAL and CHARLOTTE, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced upcoming data presentations on etripamil at being held in Atlanta, GA on May 5-8, 2024, the 2024 in Boston, MA, on May 15, 2024, and the Annual meeting of the Heart Rhythm Society, , in ...
XpresSpa Introduces IV Hydration Drip Therapy at Miami International A...
XpresSpa Introduces IV Hydration Drip Therapy at Miami International Airport Pilot program designed to expand service offerings and drive revenue growth NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), an authority in wellness solutions for people on the go, today announced the introduction of IV hydration drip therapy at its Miami International Airport (MIA) XpresSpa® location. In partnership with Revitalize IV Lounge (“Revitalize”), the new service, which offers a fast and efficient way to deliver vitamins, minerals, and amino acids dir...
Bebuzee’s Revolutionary Super App Will Disrupt US and European Markets
Bebuzee’s Revolutionary Super App Will Disrupt US and European Markets With its comprehensive suite of features, the app caters to the ever-evolving needs of modern users, providing a one-stop digital demand solution. MIAMI, May 02, 2024 (GLOBE NEWSWIRE) -- via IBN – a social platform and streaming service focused on developing and deploying America's first Super App, today announces the launch of its game-changing Super App, set to redefine the digital landscape in the United States and Europe. This all-in-one app is a testament to Bebuzee's commitment to pushing the boundaries of t...
Super League Sets First Quarter 2024 Earnings Date, May 15, 2024
Super League Sets First Quarter 2024 Earnings Date, May 15, 2024 SANTA MONICA, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Super League (Nasdaq: SLE) (the “Company”), a leading creator and publisher of content experiences and media solutions across the world’s largest immersive platforms, announced today that the Company will post its first quarter 2024 financial results after market close on Wednesday, May 15, 2024. A webinar will be held the same day at 5:00 pm Eastern Time to discuss the results. Super League First Quarter 2024 Earnings Webinar Date:Wednesday, May 15, 2024Time:5:00 pm...
Mineralys Therapeutics to Announce First Quarter 2024 Financial Result...
Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024 RADNOR, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2024, before the financial markets open on Thursday, May 9, 2024. Thursday, May 9th @ 8:30 a.m. ETDomestic:...
Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Pa...
Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia) KNOXVILLE, TN, May 02, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office has allowed patent application 17/232,393, titled “Halogenated Xanthene Composition and Method for Treating Hematologic Cancers” (formerly “”). The application covers the use of Provectus’s pharmaceutical grade rose bengal sodium (“RBS”) active pharmaceut...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.